How to avoid residual solvent when drying reverse phase HPLC fractions and prevent the formation of gums and oils.
Traditional concentration of reverse phase HPLC fractions to dryness in a Genevac HT evaporator is a fast and safe process...
List view / Grid view
News
Ofev slows disease progression in IPF and reduces risk of acute exacerbations
25 February 2016 | By Victoria White
Pooled analysis from the TOMORROW and INPULSIS trials provides further evidence that Ofev (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people...
Parkinson’s disease market to hit $3.2 billion by 2021
25 February 2016 | By Victoria White
GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period...
Orphan drug designation recommended for acalabrutinib in three indications
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
Celyad completes safety follow-up in the second dose level of patients in its NKR-2 trial
25 February 2016 | By Victoria White
The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications...
‘Seismic changes’ coming to the osteoarthritis treatment market
24 February 2016 | By Victoria White
The osteoarthritis treatment market will experience seismic changes over the next decade, according to a GlobalData analyst...
China to remain the largest hepatitis B market, says GlobalData
24 February 2016 | By Victoria White
GlobalData says China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2% by 2024...
FDA accepts and grants priority review for Allergan’s Avycaz
24 February 2016 | By Victoria White
Avycaz was first approved in the US in February 2015 for the treatment of adult patients with cIAI and cUTI caused by designated susceptible bacteria...
Automating the development of aptamer-based biological tools with Tecan
24 February 2016 | By Tecan
The ARNA Laboratory in Bordeaux, France, is using DNA and RNA aptamers to develop novel tools for biological applications...
EC grants marketing authorisation to necitumumab in NSCLC
24 February 2016 | By Victoria White
This is the first authorisation for necitumumab in Europe and follows US Food and Drug Administration (FDA) approval in November 2015...
Gilead announces results from study evaluating switching to F/TAF-based regimens from Truvada
24 February 2016 | By Victoria White
At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients...
High Pressure Homogenisation & the next generation of drug delivery: Liposomes
24 February 2016 | By Biopharma Group
Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals...
CPhI Russia 2016 opens as the country is seeking rapid upgrades to GMP standards
24 February 2016 | By CPhI
CPhI Russia @ IPhEB, organised by UBM EMEA, returns for the fourth consecutive year in Russia as business opportunities in the country remain diverse...
Once-daily Isentress formulation meets endpoints in Phase III trial
23 February 2016 | By Victoria White
ONCEMRK is evaluating an investigational once-daily formulation of Isentress (raltegravir), known as raltegravir 600 mg, for previously untreated HIV-1 infected adults...
L.B. Bohle increases turnover to EUR 48 million – Pharmaceutical industry makes use of Technology Center
23 February 2016 | By L.B. Bohle Maschinen + Verfahren GmbH
The investments in the future have paid off for L.B. Bohle Maschinen + Verfahren GmbH in the 2015 business year...
